2417134-93-9
2417134-93-9
Chemical Structure
JAK-IN-26
- CAS No.: 2417134-93-9
- Formula:C22H24N6O3
- Molecular Weight:420.46
InChIKey: FKCATCQHVCOBCX-UHFFFAOYSA-N
SMILES: O=C(C1CC1)NC2=NC=C(C(NC3=CC=CC(C4=NN(C)C=N4)=C3OC)=C2)C(CC)=O
Biological Activity: JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC50=17.2 nM)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JAK-IN-26 | 98.00% | JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC50=17.2 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Envudeucitinibum | 99.56% | Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
Keywords
